Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II single-blinded study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to standard therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.

NCT03370874

Diabetic Foot Ulcer

COMPLETED PHASE3

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.

NCT04569409

Diabetic Foot Ulcer

COMPLETED PHASE3

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465

Diabetic Foot Ulcer

COMPLETED PHASE2

Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers

NCT02394886

Diabetic Foot Ulcer

COMPLETED PHASE1

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

NCT04497805

Diabetic Foot Ulcer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALLO-ASC-DFU

Allogeneic mesenchymal stem cells

Group Type EXPERIMENTAL

ALLO-ASC-DFU

Intervention Type BIOLOGICAL

Application of ALLO-ASC-DFU sheet to diabetic foot ulcer

Standard therapy

Standard therapy for patients with diabetic foot ulcer

Group Type ACTIVE_COMPARATOR

Standard therapy

Intervention Type OTHER

Standard therapy conducted for patients with diabetic foot ulcer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALLO-ASC-DFU

Application of ALLO-ASC-DFU sheet to diabetic foot ulcer

Intervention Type BIOLOGICAL

Standard therapy

Standard therapy conducted for patients with diabetic foot ulcer

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Allogeneic mesenchymal stem cells

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is between 18 years and 80 years of age.
2. Subject is diagnosed with Type I or Type II diabetes, and had defined as diabetic foot ulcers presence of wound for more than 4 weeks at the screening visit.
3. Ulcer located the foot, and ulcer size is between 1 cm\^2 and 25 cm\^2.
4. Ulcer extends into the dermis, subcutaneous tissue, tendon or joint capsule (Wagner grade 1 or 2).
5. Ulcer is free of necrotic debris.
6. Subjects had adequate circulation to ulcer as documented by one of the methods below:

* Palpation of pulses around ulcer using Doppler exam
* Ankle Brachial index (ABI) values ranging between 0.7 and 1.3, or
* Transcutaneous Oxygen Pressure (TcPO2) \> 30 mmHg.
7. Subject is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria

1. Ulcer is of non-diabetic pathophysiology.
2. The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.
3. Subject is Human Immunodeficiency Virus (HIV) positive.
4. Subjects with severe hepatic deficiencies.
5. Subjects with a glycated hemoglobin A1c (HbA1c) level of \> 15%.
6. Subject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.
7. Subjects requiring intravenous (IV) antibiotics to treat the index wound infection.
8. Subjects with severe renal deficiencies that is uncontrolled by dialysis
9. Subjects who are pregnant or breast-feeding.
10. Subjects who are unwilling to use an "effective" method of contraception during the study.
11. Current evidence of severe infection including pus drainage from the wound site.
12. Subjects who have a clinically relevant history of alcohol or drugs abuse.
13. Subject's blood sugar is \> 450 mg/dL at postprandial.
14. Subjects who are not able to understand the objective of this study or to comply with the study requirements.
15. Subjects who are considered to have a significant disease which can impact the study by the investigator.
16. Subjects who are considered not suitable for the study by the investigator.
17. Subjects who have a history of surgery for malignant tumor within the last five years (except carcinoma in situ).
18. Subjects who are currently or were enrolled in another clinical study within 60 days of screening.
19. Subjects who have undergone wound treatments with cell therapy, dermal substitutes, or other biological therapies within the last 30 days.
20. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents to unstable dosage.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No